Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced certain preliminary first quarter of 2020 financial results.
The Zacks Analyst Blog Highlights: Vapotherm, Inogen and Invacare
Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that its management team will be presenting at the Bank of America Securities Health Care Conference 2020 on Thursday, May 14, 2020 via webcast.
Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the pricing of an underwritten public offering of 3,350,000 shares of its common stock at a price to the public of $26.00 per share. In addition, Vapotherm has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares of its common stock at the public offering price less underwriting discounts and commissions. All of the shares are being offered by Vapotherm. The offering is expected to close on May 11, 2020, subject to customary closing conditions.
Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Tuesday, May 5, 2020. Vapotherm’s management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments.
Vapotherm (VAPO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Good afternoon, and thank you for joining us for the Vapotherm first quarter 2020 financial results conference call. Joining us on today's call are Vapotherm's President and Chief Executive Officer, Joe Army; and its Vice President and Chief Financial Officer, John Landry.
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that the U.S. Food and Drug Administration (FDA) recently granted Breakthrough Device Designation for the Company’s Oxygen Assist Module (OAM).
Does Vapotherm (VAPO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced first quarter 2020 financial results.
Vapotherm (NYSE: VAPO) is that rare company that not only had a good start to the year, it's seeing things get even better because of the coronavirus pandemic. The Exeter, N.H., medical technology company specializes in products to treat respiratory diseases. When COVID-19 hit, though, sales of the company's high-velocity nasal insufflation (Hi-VNI) technology really took off.
Vapotherm, Inc. (NYSE:VAPO) ("Vapotherm"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, announced today the commencement of a proposed public offering of $75 million of its shares of common stock. All of the shares will be offered by Vapotherm. Vapotherm also expects to grant the underwriters a 30-day option to purchase additional shares of common stock in an amount of up to 15 percent of the number of shares sold in the offering.
Vapotherm (VAPO) delivered earnings and revenue surprises of -17.86% and 1.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Vapotherm (NYSE: VAPO), a medical technology company, jumped 34.2% on Wednesday, after it reported its fiscal first-quarter earnings. Vapotherm’s services are in high demand during the COVID-19 pandemic because of one of its devices. During the first quarter, Vapotherm’s revenue was $19.1 million, a 55.4% year-over-year increase.
Vapotherm (VAPO) delivered earnings and revenue surprises of 16.67% and 6.64%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
As of late, it has definitely been a great time to be an investor Vapotherm
Oxygen therapy has emerged as a necessity for COVID-19 patients.
Vapotherm, Inc. (NYSE: VAPO) ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced an update on their business in response to the COVID-19 pandemic.
Vapotherm, Inc. (NYSE: VAPO), ("Vapotherm" or the "Company"), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced fourth quarter and fiscal year 2019 financial results.